We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips Posts Earnings in Q4, Revenues Increase Y/Y, Shares Dip
Read MoreHide Full Article
Key Takeaways
PHG returned to profit in the fourth quarter as revenue increased from last year.
Comparable sales grew 7% across segments, with Personal Health up 14% and orders up 7%.
Philips sees 3-4.5% comparable sales growth and 12.5-13% adjusted EBITA margin in 2026.
Koninklijke Philips (PHG - Free Report) reported fourth-quarter 2025 earnings of €0.41 per share. The company reported a loss of €0.35 per share in the year-ago quarter.
The company’s sales increased 1.1% on a year-over-year basis to €5.09 billion. Comparable sales increased 7% year over year, which was driven by growth across all segments. The Diagnosis & Treatment segment recorded 4% growth, Connected Care recorded 7% growth, and Personal Health showed 14% growth.
Further, Philips’ comparable order intake increased 7% year over year in the fourth quarter.
Sales increased 7% year over year on a comparable basis in growth geographies. Growth geographies showed 15% growth, mainly driven by Personal Health. Comparable sales in Mature geographies grew 4% in the reported quarter, mainly driven by North America and with strong contribution from Connected Care.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Diagnosis & Treatment revenues declined 2% from the year-ago quarter to €2.40 billion. Comparable sales increased 4% year over year. Image Guided Therapy showed double-digit growth, while Precision Diagnosis was flat.
Connected Care revenues were in line year over year at €1.42 billion. Comparable sales increased 7% year over year, mainly due to double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics.
Personal Health revenues grew 9% year over year to €1.11 billion. Comparable sales increased 14% year over year, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies.
Other segment sales amounted to €155 million, up 2.6% on a year-over-year basis.
PHG’s Operating Details
Gross margin contracted 600 basis points (bps) on a year-over-year basis to 44.9% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 15.3%, which expanded 40 bps on a year-over-year basis. Moreover, selling expenses decreased 100 bps year over year to 22.5%. Research & development expenses decreased 100 bps to 8.4%.
Restructuring, acquisition-related, and other items amounted to a loss of €179 million compared with €286 million a year ago.
Philips remains on track to deliver its three-year €2.5 billion productivity program, including €0.8 billion in savings in 2025.
Phillips adjusted EBITA — the company’s preferred measure of operational performance — increased 13.4% year over year to €770 million. EBITA margin expanded 160 bps on a year-over-year basis to 15.1% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin contracted 30 bps on a year-over-year basis to 11.8%.
Connected Care’s adjusted EBITA margin was 16.5% in the reported quarter, which expanded 150 bps year over year.
Personal Health’s adjusted EBITA margin contracted 500 bps on a year-over-year basis to 23%.
PHG’s Balance Sheet
As of Dec. 31, 2025, Philips’ cash and cash equivalents were €2.40 billion compared with €1.91 billion as of Sept. 30, 2025.
Total debt was €8.084 billion compared with €8.385 billion as of Sept. 30, 2025.
Operating cash flow was €1.39 billion compared with the year-ago quarter’s €1.45 billion.
In the quarter under review, free cash flow was €1.2 billion compared with the year-ago quarter’s €1.28 billion.
PHG Initiates 2026 Guidance
Philips expects to deliver 3%-4.5% of comparable sales growth.
Further, the adjusted EBITA margin is expected to be between 12.5% and 13%.
Free cash flow is expected to be between €1.3 billion and €1.5 billion in 2026.
Analog Devices’ shares have gained 60.3% in the past 12-month period. Analog Devices is scheduled to release first-quarter fiscal 2026 results on Feb. 18, 2026.
Applied Materials shares have returned 79.8% in the past 12-month period. AMAT is scheduled to release its first-quarter fiscal 2026 results on Feb. 12, 2026.
MKS shares have gained 127.7% in the past 12-month period. MKS is set to report its fourth-quarter 2025 results on Feb. 17, 2026.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Philips Posts Earnings in Q4, Revenues Increase Y/Y, Shares Dip
Key Takeaways
Koninklijke Philips (PHG - Free Report) reported fourth-quarter 2025 earnings of €0.41 per share. The company reported a loss of €0.35 per share in the year-ago quarter.
The company’s sales increased 1.1% on a year-over-year basis to €5.09 billion. Comparable sales increased 7% year over year, which was driven by growth across all segments. The Diagnosis & Treatment segment recorded 4% growth, Connected Care recorded 7% growth, and Personal Health showed 14% growth.
Further, Philips’ comparable order intake increased 7% year over year in the fourth quarter.
Sales increased 7% year over year on a comparable basis in growth geographies. Growth geographies showed 15% growth, mainly driven by Personal Health. Comparable sales in Mature geographies grew 4% in the reported quarter, mainly driven by North America and with strong contribution from Connected Care.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
Philips’ stock lost 3.46% in pre-market trading.
PHG’s Segmental Update
Diagnosis & Treatment revenues declined 2% from the year-ago quarter to €2.40 billion. Comparable sales increased 4% year over year. Image Guided Therapy showed double-digit growth, while Precision Diagnosis was flat.
Connected Care revenues were in line year over year at €1.42 billion. Comparable sales increased 7% year over year, mainly due to double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics.
Personal Health revenues grew 9% year over year to €1.11 billion. Comparable sales increased 14% year over year, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies.
Other segment sales amounted to €155 million, up 2.6% on a year-over-year basis.
PHG’s Operating Details
Gross margin contracted 600 basis points (bps) on a year-over-year basis to 44.9% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 15.3%, which expanded 40 bps on a year-over-year basis. Moreover, selling expenses decreased 100 bps year over year to 22.5%. Research & development expenses decreased 100 bps to 8.4%.
Restructuring, acquisition-related, and other items amounted to a loss of €179 million compared with €286 million a year ago.
Philips remains on track to deliver its three-year €2.5 billion productivity program, including €0.8 billion in savings in 2025.
Phillips adjusted EBITA — the company’s preferred measure of operational performance — increased 13.4% year over year to €770 million. EBITA margin expanded 160 bps on a year-over-year basis to 15.1% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin contracted 30 bps on a year-over-year basis to 11.8%.
Connected Care’s adjusted EBITA margin was 16.5% in the reported quarter, which expanded 150 bps year over year.
Personal Health’s adjusted EBITA margin contracted 500 bps on a year-over-year basis to 23%.
PHG’s Balance Sheet
As of Dec. 31, 2025, Philips’ cash and cash equivalents were €2.40 billion compared with €1.91 billion as of Sept. 30, 2025.
Total debt was €8.084 billion compared with €8.385 billion as of Sept. 30, 2025.
Operating cash flow was €1.39 billion compared with the year-ago quarter’s €1.45 billion.
In the quarter under review, free cash flow was €1.2 billion compared with the year-ago quarter’s €1.28 billion.
PHG Initiates 2026 Guidance
Philips expects to deliver 3%-4.5% of comparable sales growth.
Further, the adjusted EBITA margin is expected to be between 12.5% and 13%.
Free cash flow is expected to be between €1.3 billion and €1.5 billion in 2026.
PHG’s Zacks Rank & Stocks to Consider
Philips currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader Zacks Computer and Technology sector include Analog Devices (ADI - Free Report) , Applied Materials (AMAT - Free Report) , and MKS (MKSI - Free Report) . While MKSI sports a Zacks Rank #1 (Strong Buy), Analog Devices and Applied Materials carry a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Analog Devices’ shares have gained 60.3% in the past 12-month period. Analog Devices is scheduled to release first-quarter fiscal 2026 results on Feb. 18, 2026.
Applied Materials shares have returned 79.8% in the past 12-month period. AMAT is scheduled to release its first-quarter fiscal 2026 results on Feb. 12, 2026.
MKS shares have gained 127.7% in the past 12-month period. MKS is set to report its fourth-quarter 2025 results on Feb. 17, 2026.